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Abstract
Background: Asthma is the most common pediatric chronic disease affecting 9.6 % of American children. Delay
in asthma diagnosis is prevalent, resulting in suboptimal asthma management. To help avoid delay in asthma
diagnosis and advance asthma prevention research, researchers have proposed various models to predict asthma
development in children. This paper reviews these models.
Methods: A systematic review was conducted through searching in PubMed, EMBASE, CINAHL, Scopus, the Cochrane
Library, the ACM Digital Library, IEEE Xplore, and OpenGrey up to June 3, 2015. The literature on predictive
models for asthma development in children was retrieved, with search results limited to human subjects and
children (birth to 18 years). Two independent reviewers screened the literature, performed data extraction,
and assessed article quality.
Results: The literature search returned 13,101 references in total. After manual review, 32 of these references
were determined to be relevant and are discussed in the paper. We identify several limitations of existing
predictive models for asthma development in children, and provide preliminary thoughts on how to address
these limitations.
Conclusions: Existing predictive models for asthma development in children have inadequate accuracy. Efforts
to improve these models’ performance are needed, but are limited by a lack of a gold standard for asthma
development in children.
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Background
Asthma is a chronic lung disease caused by airway inflam-
mation. Asthma is the most common pediatric chronic
disease [1, 2] affecting 7.1 million (9.6 %) of American
children [3, 4]. Asthma is the primary diagnosis for 1/3 of
pediatric emergency department visits [5], and the most
frequent reason for preventable pediatric hospitalization
[6] and school absenteeism due to chronic conditions [7].
In 2008, 9.3 billion dollars, or 8 % of the total direct
healthcare cost for all children, were spent on pediatric
asthma [1].
About 80 % of pediatric asthma patients have symp-
tom onset before age six [8, 9], most of them before age
three [10–12]. However, only about 1/3 of children with
at least one episode of asthmatic symptoms by age three
will have asthma at age six and over [10, 13–18]. Asthma
is under-diagnosed in 18–75 % of asthmatic children
[19–23]. Overdiagnosis of asthma is also prevalent.
Eleven percent of patients in primary care using inhaled
corticosteroids, the most potent and consistently effect-
ive long-term control medication for asthma [24, 25],
have no indication for the medication [26]. It is desirable
to construct an accurate model to predict whether a
child will develop asthma in the future. In support of the
potential of predictive models, a published predictive
model for asthma development has already been shown
to outperform a physician’s diagnosis of asthma in young
children, which had a low sensitivity of 29 % and a low
positive predictive value of 23 % [27]. Such a model can
provide several benefits.
First, appropriate asthma treatment can prevent ser-
ious asthma complications. A delay (median = 3.3 years)
in diagnosis is experienced by 2/3 of asthmatic children
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[28–34] and is associated with suboptimal or no treat-
ment for asthma [19, 20, 28, 35, 36], presenting a major
clinical and public health concern [29, 37]. Many children,
including 37 % of the 32 million American children on
Medicaid in 2013, miss regular check-ups [38]. By identi-
fying children at high risk for asthma and scheduling more
frequent follow-up with a clinician familiar with asthma,
the clinician can diagnose asthma in a timely manner and
start asthma treatment earlier [39]. This has long-term
benefits including fewer respiratory symptoms [40–47],
reduced maintenance dose of asthma control medication
[43, 48], fewer medication side effects [24], less need for
secondary medications [40, 42–44, 46–48], reduced
overuse of antibiotics [29], fewer asthma exacerbations
[31, 41–53], less school absenteeism [45, 47], fewer
caregiver work days lost [53], lower healthcare costs
[24, 43, 48, 50, 53], preserved lung function avoiding
airway remodeling (i.e., permanent alterations in the
airway structure) [31, 41, 43, 44, 47, 48, 52, 54–58],
less need for rehabilitation [50], lower risk of death from
asthma [31, 50, 59], increased chance that the patient out-
grows his/her asthma [60], and improved quality of life
[14, 54]. Moreover, timely asthma treatment can benefit
both children with severe asthma and children with mild
asthma [49, 61–63].
Second, asthma is a subjective, clinical diagnosis in
children under five [14, 64, 65]. Clinicians have difficulty
diagnosing asthma in young children [27, 64, 66]. Most
children under five cannot cooperate reliably with object-
ive lung function measurements. Also, there is no genetic
marker or diagnostic test that can reliably diagnose
asthma [64, 67, 68]. Using a predictive model can help
physicians better diagnose asthma [69, 70], particularly in
children under five.
Third, the information provided by a predictive model
can contribute directly to children’s quality of life. A low
predicted risk for asthma can alleviate concerns of the
child and his/her caregivers [71]. A high predicted risk
may help the child and caregivers understand symptoms,
improve treatment adherence, and adjust lifestyle and
living conditions to avoid exposing the child to environ-
mental contaminants and allergens [45, 72].
Fourth, proposed preventive interventions for asthma
[73–82] such as suplatast tosilate are under intensive
research worldwide [83]. Disease risk ascertainment of
enrollees is critical in studying efficacy of preventive
interventions in randomized clinical trials [84]. An
accurate predictive model can ensure enrollment of
children at risk and facilitate re-analysis of earlier trials
for more accurate estimates of efficacy.
Fifth, risk stratification through application of a predict-
ive model can help clinicians and researchers properly
weigh benefits against harms, costs, and inconvenience of
preventive interventions for asthma [71, 85].
To facilitate asthma diagnosis and prevention, re-
searchers have developed multiple models for predicting
asthma development in children. In this paper, we provide
a systematic review of these models. We present the exist-
ing models’ strengths, limitations, knowledge gaps, and
opportunities for improvement in modeling. We discuss
specific responses to selected gaps and limitations with
the hope to stimulate future research on this topic. A list
of acronyms used in this paper is provided at the end of
this paper.
Methods
This study follows the principles of the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses guideline
[86]. All study co-authors provided input to the study
protocol’s design.
Information sources
This systematic review of published literature on pre-
dictive models for asthma development in children is
limited to the period through June 3, 2015. Eight data-
bases were used: PubMed, EMBASE, CINAHL, Scopus,
the Cochrane Library, the Association for Computing
Machinery (ACM) Digital Library, IEEE Xplore, and
OpenGrey. EMBASE includes proceedings of 1000 confer-
ences each year. The ACM Digital Library and IEEE
Xplore are two major computer science literature data-
bases covering journals, magazines, newsletters, and
conference proceedings. OpenGrey is a database on grey
literature. All citations were imported into the EndNote
X7 reference management software.
Eligibility criteria
Inclusion criteria: Judgment of each retrieved reference’s
relevance was based on pre-defined inclusion criteria
ensuring that the article’s primary focus was on predict-
ive models for asthma development in children includ-
ing ≥2 attributes. To be considered a qualified report on
a predictive model, the article must report Area Under
the receiver operating characteristic Curve (AUC) sum-
marizing sensitivity and specificity, accuracy, or ≥2 of
the following four performance metrics: sensitivity, spe-
cificity, positive predictive value, and negative predictive
value. Reporting only one of the latter four performance
metrics is insufficient for demonstrating model perform-
ance, as the model can be tuned specifically to maximize
one metric by sacrificing other metrics, e.g., through a
tradeoff between sensitivity and specificity.
Exclusion criteria: Non-English references and conference
abstracts were excluded. Unlike full-length conference
papers, conference abstracts provide insufficient detail of
the study for meaningful review.
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Search strategies and study selection
The search strategies were developed by GL, MJ, and two
medical librarians (DS and MM) trained in systematic
review searches. The search queries used in the eight data-
bases are listed in the Additional file 1. Search results were
limited to human subjects and children (birth-18 years) as
outlined in the Additional file 1.
For each retrieved reference, two independent reviewers
(GL and MJ) evaluated the title and abstract to determine
potential relevancy. For each potentially relevant refer-
ence, the full text was evaluated to make a final inclusion
decision. The final literature review included articles
meeting the pre-defined inclusion criteria. GL and MJ’s
independent review results achieved a strong level of
agreement (kappa = 0.97). Disagreements about inclusion
of individual articles were addressed by discussion among
GL and MJ, and if needed a third reviewer (BS).
Data extraction and quality assessment
Two independent reviewers (GL and MJ) extracted the
following article details using a data abstraction spread-
sheet: purpose for making the prediction, study popula-
tion, population size, methods used for building predictive
models, predictors used, and the models’ performance.
These two reviewers also assessed each included article’s
quality using the following eight questions adapted from
the Critical Appraisal Skills Programme (CASP) clinical
prediction rule checklist [87]:
Q1: Is the predictive model clearly defined?
Q2: Did the population from which the predictive model
was derived include an appropriate spectrum of
patients?
Q3: Was the predictive model validated in a different
group of patients?
Q4: Were the predictor variables and the outcome
evaluated in a blinded fashion?
Q5: Were the predictor variables and the outcome
evaluates in the whole sample selected initially?
Q6: Are the statistical methods used to construct and
validate the predictive model clearly described?
Q7: Can the performance of the predictive model be
calculated?
Q8: Was the estimate of the predictive model’s per-
formance precise?
The CASP clinical prediction rule checklist was de-
signed specifically for evaluating the quality of predictive
modeling studies. Any discrepancy in review assessment
was resolved by discussion between GL and MJ, and if
needed a third reviewer (BS).
Results
As shown in Fig. 1, the literature search returned 13,101
references in total, of which 74 were potentially relevant
after review of titles and abstracts and underwent full-text
review. Of those fully reviewed, 32 references describing 30
predictive models met inclusion criteria and are discussed
in this paper. The other 42 were excluded because they do
not primarily focus on predictive models for asthma devel-
opment in children including ≥2 attributes. The included
articles include only studies on predictive models. No
systematic reviews or randomized controlled trials were
found. In this section, we describe the state of the art of
predictive models for asthma development in children. A
summary of the predictive models for asthma development
in children is given in Table 1. Our narrative description
and the content of Table 1 are based on article details
extracted into the data abstraction spreadsheet, with
additional information to provide context. For the question
Q3 used for assessing article quality, the answer is “no” for
nine included articles [17, 65, 71, 88–93] and “yes” for the
other 23 included articles. For each of the other seven
questions Q1, Q2, and Q4–Q8 used for assessing article
quality, the answer is “yes” for each included article.
Predictive models developed for the general child
population
Twenty-three models for predicting asthma development
have been developed for the general child population.
These models fall into the following categories: clinical
index [94–100], logistic regression [17, 88, 90–92, 101, 102],
Fig. 1 Flowchart of the article selection process
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Table 1 Categorization of existing predictive models for asthma development in children




















Clinical index Seven predictors collected from a
parental questionnaire: early
wheeze, early frequent wheeze,
parental asthma, eczema, blood
eosinophilia, wheezing without
colds, and allergic rhinitis
The loose asthma predictive index:
sensitivity = 57 %, specificity = 81 %,
positive predictive value = 26 %,
negative predictive value = 94 %
[94]
The stringent asthma predictive
index: sensitivity = 28 %,
specificity = 96 %, positive
predictive value = 48 %, negative
predictive value = 92 % [94]
Chang et al.
[97] (2013)
Children at age 1–3 289 Asthma development
at age 6–11
Clinical index Early wheeze, early frequent
wheeze, parental asthma, eczema,
blood eosinophilia, wheezing
without colds, allergic sensitization
to aeroallergens, allergic
sensitization to milk, eggs, or
peanuts
Sensitivity = 17 %, specificity = 99 %,
positive predictive value = 72 %,
negative predictive value = 91 %
Amat et al.
[100] (2011)
Children under age three
with a history of ≥3
wheezing episodes and
having been assessed for
respiratory wheezing
disease using a standardized





Sensitivity = 87 %, specificity = 37 %,
positive predictive value = 61 %,
negative predictive value = 71 %,
AUC = 0.62, accuracy = 69 %
Singer et al.
[98] (2013)
Children aged 3 months–




Clinical index Early wheeze, early frequent
wheeze, parental asthma, eczema,
elevated fraction of exhaled nitric
oxide (FeNO), wheezing without
colds, allergic rhinitis
Sensitivity = 75 %, specificity = 62 %,
positive predictive value = 58 %,
negative predictive value = 78 %
Amin et al.
[99] (2014)
Children at age three with
≥1 parent with a positive
skin prick test
589 Objectively confirmed
asthma at age seven
Clinical index Frequent wheezing, parental
asthma, allergic sensitization to
≥1 aeroallergens, a history of
eczema, wheezing without a cold,
allergic rhinitis, allergic sensitization
to milk or egg
Sensitivity = 44 %, specificity = 94 %,
positive predictive value = 60 %,
negative predictive value = 89 %
Klaassen et al.
[101] (2015)




Logistic regression The original asthma predictive
index [94], exhaled volatile organic
compounds, gene expression
AUC = 0.86
Zhang et al. [88]
(2014)
Children aged 2–20 months
with the first episode of
wheezing
128 Multi-trigger wheezing
in the next two years
Logistic regression Wheezing severity score computed
using the Preschool Respiratory
Assessment Measure scoring scale,
number of shed exfoliated airway
epithelial cells, family or personal
history of atopic disease
Sensitivity = 95 %, specificity = 74 %,
positive predictive value = 59 %,
negative predictive value = 94 %
Children at age four 1034 in [89],
936 in [103]
Persistent wheezing
at age 10 (wheezing
Cumulative risk
score



















Table 1 Categorization of existing predictive models for asthma development in children (Continued)
Kurukulaaratchy
et al. [89, 103]
(2003, 2010)
onset by age four
and still wheezing
at age 10)
history of asthma, recurrent chest
infections at age two, atopic skin
prick testing at age four, and
absence of nasal symptoms at
age one
Sensitivity = 53 %, specificity = 85 %,
positive predictive value = 68 %,
negative predictive value = 74 % [89]
Sensitivity = 22 %, specificity = 97 %,
positive predictive value = 65 %,




Children at age two 693 Asthma development
at age 21
Logistic regression Four predictors collected from a
parental questionnaire: female
gender, smoking mother, lower
respiratory tract illness before
age two, and atopic parents
AUC = 0.66, sensitivity = 53 %,
specificity = 70 %, positive
predictive value = 20 %, negative
predictive value = 91 %
Children at age four Four predictors collected from a
parental questionnaire: female
gender, smoking mother, lower
respiratory tract illness between
ages two and four, and atopic
parents
AUC = 0.68, sensitivity = 71 %,
specificity = 53 %, positive
predictive value = 18 %, negative
predictive value = 93 %
Clough et al.
[17] (1999)
Children aged 3–36 months
with first wheezing in the
previous 12 weeks and at




Logistic regression Age, serum soluble interleukin-2
receptor (IL-2R) level
Accuracy = 71 %, sensitivity = 57 %,
specificity = 84 %, positive
predictive value = 76 %, negative
predictive value = 68 %
Devulapalli et al.
[104] (2008)
Children at age two 449 Asthma development
at age 10
Severity score Three predictors collected from a
parental questionnaire: number of
episodes of bronchial obstruction,
number of months with persistent
bronchial obstruction, and number
of hospital admissions due to
bronchial obstruction
AUC = 0.78, sensitivity = 56 %,
specificity = 86 %, positive
predictive value = 53 %, negative
predictive value = 88 % when the
severity score was cut off at 5
Marenholz et al.
[105] (2009)





Filaggrin gene mutation, increased
immunoglobulin E (IgE) levels to
food allergens
Sensitivity = 9 %, specificity = 99 %,
positive predictive value = 73 %,
negative predictive value = 80 %
Infants with eczema Sensitivity = 17 %, specificity = 100 %,
positive predictive value = 100 %,




Children at age five with
an asthma diagnosis
112 Continued asthma







Four predictors collected from a
questionnaire: cough, bronchiolitis
episodes until age five, wheezing,
and asthma diagnosis [106]






46 predictors collected from a
questionnaire [107]
Accuracy = 96 %, sensitivity = 95 %,


























Nine predictors collected from a
questionnaire: wheezing episodes
until age five, wheezing episodes
between ages three and five,
wheezing episodes until age three,
weight, waist’s perimeter, seasonal
symptoms, FEF25/75, number of
family members, and corticosteroids
inhaled [108]
Accuracy = 97 %, sensitivity = 96 %,







Eight predictors collected from a
questionnaire: cough, bronchiolitis
episodes until age five, until age
three, between ages three and five,
at age two, at age three, at age
four, and at age five [109]
Accuracy = 100 %, sensitivity = 100 %,
specificity = 100 % [109, 110]
Ten predictors collected from a
questionnaire: cough, asthma
diagnosis, total number of
bronchiolitis episodes until age five,
bronchiolitis episodes until age
three, between ages three and five,
until age four, at age one, at age
two, at age three, and at age five
[110]
Lødrup Carlsen
et al. [91] (2010)
Children at birth 614 Asthma development
by age 10
Logistic regression Female gender, family network,
alcohol in pregnancy, parental
rhinoconjunctivis, parental
education, lung function at birth
(resistance≤median, Ve≤median,
tPTEF/tE≤ 0.2)
AUC = 0.74, sensitivity = 75 %,
specificity = 64 %, positive
predictive value = 35 %, negative
predictive value = 91 %
Spycher et al.
[92] (2012)
Children at birth 5677 Asthma development
at age 7–8








Logistic regression Antibiotic use in the child’s first
year of life, family history of atopic

















Measurements of volatile organic
compounds excreted in breath


















Table 1 Categorization of existing predictive models for asthma development in children (Continued)
For the primary
care setting














Logistic regression Family history of asthma, atopic
dermatitis, multiple allergen
sensitizations
AUC = 0.66, sensitivity = 42 %,
specificity = 90 %, positive
predictive value = 67 %, negative




Children aged 0–4 at the
first time of having
asthma-like symptoms in
the primary care setting
2171 in [27] Asthma development
at age 7–8
Logistic regression Eight predictors collected from a
parental questionnaire: male
gender, post-term delivery, parental
education, parental inhaled
medication, wheezing frequency,
wheeze/dyspnea apart from colds,
respiratory infections, and eczema
AUC = 0.74, sensitivity = 36 %,
specificity = 91 %, positive
predictive value = 32 %, negative
predictive value = 92 %
2877 in [9] Asthma development
at age six




from colds, respiratory infections,
eczema
AUC = 0.75, sensitivity = 37 %,
specificity = 92 %, positive
predictive value = 22 %, negative
predictive value = 96 % when the
asthma risk score corresponding to
the model was cut off at 12
van der Mark
et al. [71] (2014)
Children aged 1–5
previously presented to




438 Asthma diagnosis at
age six
Logistic regression Age, family history of asthma or
allergy, wheezing-induced sleep
disturbances, wheezing in the
absence of common colds,
specific IgE for cat, dog, and
house dust mite
AUC = 0.73, positive predictive
value = 22 %, negative predictive
value = 78 % when the asthma
prediction score corresponding to
the model was cut off at 3
Eysink et al. [65]
(2005)
Children aged 1–4 who
visited their primary care
physicians for persistent
coughing of ≥5 days
123 Asthma development
at age six
Logistic regression Age, family history of pollen allergy,
wheezing, specific IgE for cat, dog,




Children aged 1–3 who
visited their primary care







Logistic regression Gender, age, wheeze without colds,
wheeze frequency, activity
disturbance, shortness of breath,
exercise-related wheeze/cough,
aeroallergen-related wheeze/cough,
eczema, parental history of asthma/
bronchitis
AUC = 0.76, sensitivity = 72 %,
specificity = 71 %, positive
predictive value = 49 %, negative
predictive value = 86 % when the
asthma prediction score
corresponding to the model was





Children at age two
previously hospitalized for
bronchiolitis during infancy
93 Asthma diagnosis at
age 11
Logistic regression Four predictors collected from a
parental questionnaire: recurrent
wheezing, parental atopy, parental
asthma, and atopic dermatitis
Sensitivity = 65 %, specificity = 82 %,
positive predictive value ≈ 50 %,


















cumulative risk score [89, 103], severity score [104],
combination of two attributes [105], and machine
learning models [106–111]. 17 models target children at
or under age four [17, 88–92, 94–101, 103–105, 111]. Six
of 24 studies target children with wheezing or coughing
symptoms [17, 88, 98, 100, 101, 111]. Sixteen models
used predictors collected from a (parental) question-
naire [89, 90, 94–98, 100–104, 106–110] and family
history [88–91, 94–103, 107]. Three models used
genetic information [92, 101, 105].
Different studies used differing prediction targets, candi-
date predictors, and populations, affecting the predictors
included in the final predictive models. Age and gender
were used in the predictive models in Clough et al. [17]
and Balemans et al. [90, 91], respectively, but were
non-predictive for the prediction target in Zhang et
al. [88]. Eczema, maternal smoking, and rhinitis were
used in the predictive models in Castro-Rodríguez et al.
[94–100], Balemans et al. [90], and Castro-Rodríguez et al.
[94–96, 98, 99], respectively, but had no independent
significance for the prediction target in Kurukulaaratchy
et al. [89]. Food allergy was used in the predictive models
in Chang et al. [97, 99, 100, 105], but did not highly
correlate with the prediction target in Kurukulaaratchy
et al. [89].
Castro-Rodríguez et al. [94] published in 2000 one of
the first work on predictive modeling for asthma devel-
opment in children, where two clinical indices were
built: the loose asthma predictive index and the strin-
gent asthma predictive index. Both asthma predictive
indices have since been externally validated, with results
comparable to those of the initial study [95, 96, 98]. In
addition, both asthma predictive indices have since
been updated by several researchers: (1) Guilbert et al.
[12] in 2004 updated the stringent asthma predictive
index through replacing the predictor of allergic rhin-
itis by allergic sensitization to aeroallergens and aller-
gic sensitization to milk, eggs, or peanuts [97]. (2)
Singer et al. [98] in 2013 updated the original asthma
predictive index through replacing the predictor of
blood eosinophilia by elevated fraction of exhaled ni-
tric oxide (FeNO) to avoid invasive blood sampling. (3)
Amin et al. [99] in 2014 updated the original asthma
predictive index by using the predictors of frequent
wheezing, parental asthma, allergic sensitization to ≥1
aeroallergens, a history of eczema, wheezing without a
cold, allergic rhinitis, and allergic sensitization to milk
or egg.
Most models (17 of 23) for predicting asthma develop-
ment for the general child population have low accuracy,
typically with a sensitivity, positive predictive value, or
AUC much less than 80 %. There are several exceptions,
all with unknown performance for the situation of inter-
est to this review:
(1) The model built by Klaassen et al. [101] achieved an
AUC of 0.86. In the study, prevalence of future
asthma development was adjusted in the validation
set through stratified sampling. It is unclear how
the model would perform in the general child
population, where the prevalence of future asthma
development remains unmodified.
(2) Chatzimichail et al. performed five studies and built
one machine learning model per study [106–110].
Each study used many candidate predictors and
built a model achieving an accuracy ≥95 %.
Each study excluded patients with missing data
representing 24 % of all patients, incurring a large
selection bias. The five models predict persisting
asthma in children already diagnosed. In this
review, we are interested in models predicting
asthma development in children who have not
received an asthma diagnosis. The five studies
illustrate the potential benefits of including multiple
attributes and using machine learning methods in
building models.
Besides the above exceptions, there are two other studies
that built models with unknown performance for the
situation of interest to this review. First, for children at age
two, Devulapalli et al. [104] in 2008 conducted a case–con-
trol study and developed a severity score to predict asthma
development at age 10. The study matched children with
recurrent bronchial obstruction (≥2 episodes) to children
without bronchial obstruction. Since having recurrent
bronchial obstruction increases a child’s asthma risk, the
matching process greatly inflated the prevalence of future
asthma development in the study population. It is unclear
how the model would perform in the general child popula-
tion, where the matching process is absent.
Second, for children aged 6–24 months with ≥3 epi-
sodes of physician-diagnosed wheezing treated with bron-
chodilators or corticosteroids, Elliott et al. [112] in 2013
used single-breath FeNO >30 parts per billion (p.p.b.) to
predict persistence of wheezing at age three. The predic-
tion method achieved an AUC of 0.86, a low sensitivity of
77 %, a specificity of 94 %, a positive predictive value of
95 %, and a low negative predictive value of 73 %. Obtain-
ing single-breath FeNO measurements requires sedating
the child, special equipment, and special technical expert-
ise. It is unknown how feasible the method will be in pre-
dicting asthma development in children. The study used a
highly selected population that may have a high pre-test
probability of continued wheezing at age three.
Predictive models developed for the primary care setting
Six models for predicting asthma development in chil-
dren have been developed for the primary care setting.
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In this setting, we prefer predictors that are accurate
and non-invasive, easy, and inexpensive to obtain [90].
Among all models for predicting asthma development
in children in the primary care setting, two [27, 113]
have been externally validated [96, 114] with results
comparable to those of the initial studies. With one
exception [71], all models target children at or under age
four. Three of six models used predictors collected from
a parental questionnaire [9, 27, 71]. All models are based
on logistic regression, target children with asthma-like
symptoms such as wheezing, and used family history
information. No model used genetic information.
Different studies used differing prediction targets, candi-
date predictors, and populations, affecting the predictors
included in the final predictive models. Age was used in
the predictive models in Eysink et al. [65, 71, 113, 114],
but was non-predictive for the prediction target in Vial
Dupuy et al. [18]. Gender was used in the predictive
models in Caudri et al. [9, 27, 113, 114], but was non-
predictive for the prediction targets in Vial Dupuy et al.
[18, 71]. Parental asthma was used in the predictive
models in Vial Dupuy et al. [18, 71, 113, 114], but had no
independent significance for the prediction target in Cau-
dri et al. [9, 27]. Parental education was used in the pre-
dictive model in Caudri et al. [9, 27], but was not collected
in the studies in Vial Dupuy et al. [18, 65, 71, 113, 114].
For children aged 0–4 at the first time of having asthma-
like symptoms in the primary care setting, Caudri et al.
[27] in 2009 built a logistic regression model to predict
asthma development at age 7–8. The model achieved a low
AUC of 0.74, a low sensitivity of 36 %, a specificity of 91 %,
a low positive predictive value of 32 %, and a negative
predictive value of 92 %. In comparison, in the year when
asthma-like symptoms were first reported, a physician’s
diagnosis of asthma had a low sensitivity of 29 %, a specifi-
city of 88 %, a low positive predictive value of 23 %, and a
negative predictive value of 91 %. Thus, the model per-
formed better than a physician’s diagnosis of asthma.
Most models (five of six) for predicting asthma devel-
opment in children in the primary care setting have low
accuracy, typically with an AUC much less than 80 %.
There is only one exception with unknown performance
for the situation of interest to this review. The model
built by Eysink et al. [65] achieved an AUC of 0.87 using
a case–control design matching IgE-positive children to
IgE-negative children. The matching process excluded
most children as they were IgE-negative. Since being
IgE-positive increases a child’s asthma risk, the matching
process greatly inflated the prevalence of future asthma
development in the study population. It is unclear how
the model would perform in routine clinical practice,
where the matching process is absent. On a typical,
clinically relevant child population in primary care, we
would expect the model built in Eysink et al. [65] to
perform worse than that built in van der Mark et al.
[71], because the predictors used in the former are
roughly a subset of those used in the latter while both
models were developed using the same statistical method.
The model built in van der Mark et al. [71] achieved a low
AUC of 0.73.
Predictive models developed for bronchiolitis patients
Asthma is highly associated with bronchiolitis, a disease
primarily of children under age two. Bronchiolitis is in-
flammation of bronchioles, the smallest air passages in the
lungs. In cases of asthma between ages 4 and 5.5, 31 % are
heralded by clinically significant bronchiolitis during
infancy that incurred an outpatient clinic visit, emer-
gency department visit, and/or hospitalization [115].
By age two, >1/3 of children have experienced clinically
significant bronchiolitis [116]. Between 14 and 40 % will
eventually be diagnosed with asthma [117, 118], with the
risk persisting into adulthood [117, 119–125]. In general,
experiencing clinically significant bronchiolitis increases a
child’s asthma risk 2–10 times [115, 117, 119–126].
For bronchiolitis patients, various predictors of recur-
rent wheezing and emerging asthma have been identified
in the research literature [39, 69, 84, 119, 124, 127–154]:
male gender, race, type of virus causing bronchiolitis,
atopic dermatitis, family history of asthma, parental atopy,
repeated wheezing at ages 0–1 and 1–2, early sensitization
to common food and inhalation allergens, elevated blood
eosinophils (blood eosinophilia), low serum vitamin D
level, birth length, high birth weight, high weight gain from
birth to hospitalization for bronchiolitis, serum eosinophil-
derived neurotoxin level at 3 months after hospitalization
for respiratory syncytial virus (RSV) bronchiolitis, high
maternally derived RSV neutralizing antibody level in cord
blood, breastfeeding <3 months, moisture in the home
environment, exposure to secondhand smoke, no daycare
attendance, exposure to high levels of dog allergen, swim-
ming in chlorinated pools before age two, and the follow-
ing factors during (RSV) bronchiolitis: elevated IgE values,
quantity of RSV-specific IgE produced, high serum eosino-
phil cationic protein concentration, nasal eosinophil, high
CCL5 (previously known as RANTES) level in nasal epi-
thelia, signs of airflow limitation, monocyte interleukin-10
(IL-10) level, creola bodies in the sputum, and low serum
level of soluble CD14.
For children at age two previously hospitalized for bron-
chiolitis during infancy, Mikalsen et al. [93] in 2013 built a
logistic regression model to predict asthma diagnosis at
age 11. Four predictors collected from a parental question-
naire were used: recurrent wheezing, parental atopy, paren-
tal asthma, and atopic dermatitis. The model achieved a
low sensitivity of 65 %, a specificity of 82 %, a low positive
predictive value around 50 %, and a negative predictive
value around 89 %.
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Discussion
Existing predictive models for asthma development in
children have several limitations. We now describe
these limitations and identify several opportunities to
improve predictive models for asthma development in
children.
Using clinical data
Most existing predictive models for asthma development
in children were developed using medical research data
collected specifically for the study, typically through a
parental questionnaire [71]. Medical research data repre-
sent an ideal scenario atypical in practice, as they are
much more robust (complete, consistent) than clinical
data routinely collected in the electronic medical record
in clinical practice. Also, medical research data often
include additional variables not routinely collected in
clinical practice. To be useful in routine clinical practice,
a predictive model for asthma development in children
should be developed using clinical data rather than med-
ical research data. Such a model is suitable for imple-
mentation in an electronic medical record as a decision
support tool.
Making prediction at the right time
Most existing predictive models for asthma development
in children make predictions at a time unsuitable for
making clinical impact. This reduces these models’ clin-
ical value.
Usually, a physician can use a predictive model for
asthma development to facilitate asthma diagnosis and/or
prevention only if the child comes to seek medical atten-
tion [27]. A patient healthcare visit, ideally for asthma-like
symptoms [18], is the best time for the physician to pre-
scribe preventive interventions for asthma and to schedule
follow-up visits. However, most existing predictive models
for asthma development make predictions outside of a
patient healthcare visit, often when the children are at a
fixed age [27]. Also, if a child is not having asthma-like
symptoms at that time, it would be difficult to motivate
the child and his/her parents to comply with preventive
interventions and follow-up visits [55]. So far, none of the
existing predictive models for asthma development in
children works for all types of patient healthcare visits
(outpatient clinic visit, emergency department visit, and
hospitalization).
Most existing predictive models for asthma develop-
ment in children were developed for relatively old
children, with a median age between two and four.
This age is too late for effective application of prevent-
ive interventions for asthma. Many preventive inter-
ventions are intended to modify the natural course of
asthma, particularly to prevent airway remodeling and
eosinophilic inflammation. Airway remodeling and
eosinophilic inflammation have not occurred in
children with asthma-like symptoms before age two,
but are already present in asthmatic children at age
two [37, 155].
To be useful in routine clinical practice, a predictive
model for asthma development in children should make
predictions during patient healthcare visits (possibly for
asthma-like symptoms) and before children reach age
two. Ideally, the model should work for all types of
patient healthcare visits. In general, children at high
risk for asthma should be identified as early as pos-
sible [10, 17, 18, 156]. However, this does not mean that
every preventive or treatment intervention for asthma
should be started immediately when a child is first
predicted to be at high risk for asthma. Yoshihara [37]
suggested that starting inhaled corticosteroids before age
one is possibly too early and likely to have no effect on the
natural history of asthma. Instead, early intervention with
anti-inflammatory medications such as inhaled corticoste-
roids should possibly occur between ages one and three.
Improving prediction accuracy
As mentioned in the introduction, predictive models
for asthma development in children are developed to
facilitate asthma diagnosis and prevention. Asthma is
a non-communicable disease occurring in a minority
of children. Medications that can potentially prevent
asthma have side effects [55]. It is costly and unethical to
give such a medication to a large proportion of children,
particularly young children, for asthma prevention if they
will not benefit from the medication [40, 55, 156]. The
case for other interventions for asthma prevention or
treatment is similar.
To be clinically valuable, a predictive model for asthma
development in children needs to have both high positive
predictive value and high sensitivity [157]. High positive
predictive value ensures that a child with high predicted
risk is indeed likely to develop asthma. High sensitivity en-
sures that the model can identify most children who will
develop asthma in the future.
As reviewed in Results section, every existing predict-
ive model for asthma development in children has a low
AUC, a low sensitivity, and/or a low positive predictive
value, typically all much less than 80 %. At present, no
such model can attain accuracy high enough for routine
clinical use [39, 71, 84]. It remains an open problem to
improve the accuracy of predicting asthma development
in children. There are several potential approaches for im-
proving accuracy, including machine learning methods,
using large data sets and exhaustive variable sets, and
focusing on a child population with a high prevalence of
future asthma development. We now describe these
approaches individually.
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Using machine learning methods
Most existing predictive models for asthma development
in children are based on the statistical method of logistic
regression. Except for those described in Chatzimichail
et al. [106–111], the other existing predictive models are
based on either risk score or combination of risk factors.
As is the case with predictive modeling in general,
machine learning methods such as support vector ma-
chines and random forests often achieve higher pre-
diction accuracy than risk score, combination of risk
factors, and logistic regression [158]. It would be interest-
ing to compare various machine learning methods for pre-
dicting asthma development in children. Traditionally,
risk score, combination of risk factors, and logistic regres-
sion have two advantages over machine learning models:
easier to use and easier to interpret [159]. Through inte-
gration into a decision support tool, machine learning
models can be made easy to use. Recently, a new method
was developed to automatically explain the prediction
results of any machine learning model without losing
prediction accuracy [160]. After overcoming the barriers
of difficulty in use and model interpretability, machine
learning models would have no major disadvantages
compared to risk score, combination of risk factors, and
logistic regression.
Using large data sets and exhaustive variable sets
With rare exceptions [9, 27, 92], existing predictive
models for asthma development in children were devel-
oped using small data sets including (typically much)
fewer than 2000 children. In general, a predictive model’s
accuracy improves as the training data set becomes larger,
particularly if the model uses many predictors. By using
data of more children to train the predictive models for
asthma development in children, we are likely to improve
the predictive models’ accuracy.
Many risk factors for asthma development are known
in the literature [94, 161–169]. However, with few excep-
tions [91, 102, 106–111], most existing predictive models
for asthma development in children use ≤10 attributes.
By using an exhaustive set of variables coupled with a
large number of children, we are likely to further im-
prove the predictive models’ accuracy.
Focusing on a child population with a high prevalence of
future asthma development
The positive predictive value of a model for predicting
development of a disease depends critically on the preva-
lence of future development of the disease. The model’s
positive predictive value improves as the prevalence in-
creases [170, 171]. If the prevalence is low, which is the
case for asthma in the general population, the model’s
positive predictive value will not be close to 1 even if the
model has both high sensitivity and high specificity [171].
This is easy to understand. In the general child population,
most children are not prone to develop asthma in the
future. Thus, the signal for future asthma development is
weak and difficult to detect.
To address this issue and improve the predictive
model’s positive predictive value, we can focus on a sub-
set of children with a high prevalence of future asthma
development rather than apply the model to the general
child population [170]. The subset of children experien-
cing clinically significant bronchiolitis is one good such
subset for several reasons. First, as mentioned at the
beginning of Predictive models developed for bronchio-
litis patients section, this subset of children not only has
a high prevalence of future asthma development, but
also includes a significant portion of children who will
eventually develop asthma. Second, in this subset of chil-
dren, attributes related to clinically significant bronchio-
litis can provide additional information to help improve
the prediction accuracy. Third, bronchiolitis mainly oc-
curs before age two. As explained in Making prediction
at the right time section, a healthcare visit for bronchio-
litis is a good time to predict a child’s risk of developing
asthma in the future.
So far, only one model has been developed for predict-
ing which bronchiolitis patients will develop asthma in
the future [93]. This model focuses on children at age
two previously hospitalized for bronchiolitis during in-
fancy and has two major shortcomings. First, the predic-
tion is made at the time the child is at age two and
outside of patient healthcare visit. As explained in Making
prediction at the right time section, this is not a good time
to make prediction. Second, among all children experien-
cing clinically significant bronchiolitis, only ~10 % (3 % of
the general child population) are hospitalized for
bronchiolitis [115, 116]. Hence, the model can iden-
tify only a small portion of children who will eventu-
ally develop asthma [115]. The narrow applicability
limits the model’s usefulness.
To overcome these two shortcomings, it would be
desirable to develop models for children experiencing
clinically significant bronchiolitis and predict, during
patient healthcare visits for bronchiolitis, which patients
will develop asthma in the future. Among all children
with clinically significant bronchiolitis, a subgroup ana-
lysis based on the type of healthcare visit (outpatient clinic
visit, emergency department visit, and hospitalization)
could evaluate how models perform on different sub-
groups of children. In this case, the subgroup of bronchio-
litis patients in the emergency department observation
unit can be either handled separately or combined into
the subgroup of hospitalized patients [115].
As mentioned in Luo et al. [172], to build such
predictive models, we should use risk factors for asthma
development known in the literature [94, 161–169] rather
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than only those for bronchiolitis patients. These risk
factors include both patient characteristics and environ-
mental factors [173]. As one predictive model does not fit
all [103], we should develop separate predictive models
for children presenting with bronchiolitis at <6, 6–12, and
13–24 months of age [174]. As boys and girls have
different likelihood of developing asthma, it could be
desirable to develop separate predictive models for
different genders [175].
Using an appropriate definition of asthma
Different predictive models for asthma development in
children used differing asthma definitions and predicted
asthma development by various ages. This diversity im-
pacts estimated asthma prevalence rates and the models’
prediction results [176]. At present, there is no consen-
sus on the optimal asthma definition or age cutoff [157].
For developing a predictive model for asthma develop-
ment in children, we would advocate starting from a
conservative asthma definition ensuring the existence of
asthma with high likelihood. One such definition is used
in Schatz et al. [177]: a patient is considered to have
asthma if he/she has (1) at least one ICD-9 diagnosis
code of asthma (493.xx) or (2) two or more asthma-related
medication dispensing (excluding oral steroids) in a 1-year
period, including β-agonists (excluding oral terbutaline),
inhaled steroids, other inhaled anti-inflammatory drugs,
and oral leukotriene modifiers. Using a conservative
asthma definition helps identify the predictors of true
asthma and estimate the risk for true asthma. Then if
necessary, we can broaden the scope of this definition in
various ways and see how the predictive model performs
with different definitions.
A child who will ever develop asthma can benefit from
both timely asthma diagnosis and preventive interven-
tions for asthma, even if he/she may outgrow his/her
asthma later in life [60, 178]. Hence, we would advocate
the prediction target (i.e., the dependent variable) to be
ever development of asthma by a certain age rather than
active asthma at a certain age. To help select an appro-
priate cut off age for asthma development, we can plot
the cumulative rate of ever development of asthma vs.
age [8, 16, 167]. The age at which the cumulative rate of
ever development of asthma starts to level off can be an
appropriate cut off point, as it ensures including most
children who will ever develop asthma.
Main findings
Substantial effort has been invested in predictive models
for asthma development in children. Although consider-
able progress has been made, much remains to be done
for these models to be useful in clinical practice. We
have identified several limitations and open problems in
predictive modeling for asthma development in children.
In particular, prediction accuracy is inadequate. We have
provided some preliminary thoughts on how to address
these limitations and open problems. This establishes a
foundation for future research on this topic.
So far, no study has deployed a predictive model for
asthma development in children in clinical practice and
demonstrated the model’s impact on clinicians’ behavior
and clinical outcome [157]. It would be desirable to
develop an accurate predictive model and then deploy it
in clinical practice to measure its clinical impact, begin-
ning at a single institution and later expanding to
multiple institutions. This is essential for ensuring the
model’s generalizability and for the model to be widely
accepted by clinicians.
Limitations
This systematic review has several limitations. First, by
excluding articles not written in English, we may have
missed predictive models for asthma development in
children published in other languages. Second, there
may be other predictive models for asthma development
in children that have never been published and hence
are missed in this systematic review. Third, few studies
directly compare predictive models on the same child
population. Performance metrics such as the AUC should
not be used to directly compare predictive models across
different child populations. Fourth, there is no clear gold
standard for the prediction target of asthma development
in children. Even if the approach described in Using
an appropriate definition of asthma section is used to
define the prediction target, the resulting definition
would still be imperfect. For instance, no existing method
can tell exactly which children under five have asthma, as
asthma is a subjective, clinical diagnosis in this age group
[14, 64, 65]. Without a gold standard definition of asthma
development, it is difficult to compare the performance of
different predictive models. Thus, investigation and con-
sensus on the appropriate definition of asthma develop-
ment is needed for future efforts on developing new
predictive models to be clinically and widely meaningful.
Conclusions
We systematically reviewed the literature on predictive
models for asthma development in children. Existing
models have several limitations. In particular, prediction
accuracy is inadequate for clinical use of any existing
model. Future studies will need to address these limita-
tions to achieve optimal predictive models. More specific-
ally, to be useful in routine clinical practice, a good
predictive model should use clinical data, make prediction
at a time suitable for making clinical impact, have high
accuracy, and use an appropriate definition of asthma.
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